Aquinox Pharmaceuticals, Inc

Aquinox Pharmaceuticals Announces Second Quarter 2014 Financial Results

Conference Call at 4:45 pm Eastern Time Today

VANCOUVER, British Columbia, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today provided a corporate update and reported financial results for the second quarter ending June 30, 2014.

"We continue to make progress with our Phase 2 trials of AQX-1125 and are pleased to announce an accepted IND for the FLAGSHIP trial. This is in addition to the IND for our LEADERSHIP trial announced in June of this year, with U.S. sites being added for both trials. Obtaining feedback and acceptance from the FDA will aid our current trials and future development planning," said Mr. David Main, President and CEO of Aquinox.

"Our Phase 2 trials are both approximately 50% enrolled but may require additional time than originally forecast to complete. We are confident that with geographic expansion into the U.S. and other jurisdictions we are well positioned to maximize enrollment for the trials' remaining duration."

Aquinox now expects to report top-line data from both LEADERSHIP and FLAGSHIP trials in the first half of 2015. In addition to LEADERSHIP and FLAGSHIP, Aquinox has selected two new disease indications to initiate exploratory Phase 2 trials: chronic rhinosinusitis and atopic dermatitis. Financial results are in line with expectations and existing cash balances are expected to be sufficient to complete both ongoing Phase 2 trials and planned exploratory Phase 2 trials.

Business Highlights

Summary of Financial Results

In conjunction with the reporting of these financial results, Aquinox will be hosting its biannual conference call and webcast on August 11, 2014, at 4:45 PM Eastern Time (1:45 PM Pacific). Participants can join the call at 1-866-357-7878 (North America) or 1-315-625-3088 (International) with the conference ID 83462572. The live audio webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at

About Aquinox Pharmaceuticals, Inc.

Aquinox is a clinical-stage pharmaceutical company discovering and developing novel, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase 1 ("SHIP1") for the treatment of inflammatory disease and cancer. For more information please visit

Cautionary Note on Forward-looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to data availability from ongoing clinical trials and initiation of future clinical trials. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; our expectations regarding the potential safety, efficacy or clinical utility of AQX-1125; and reasons outside of our control. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Aquinox is contained in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 filed with the Securities and Exchange Commission. Aquinox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Brendan Payne,
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604-629-9223 Ext. 109

Bianca Nery
Senior Account Executive
MacDougall Biomedical Communications

Condensed consolidated and combined balance sheets
(Unaudited) (Expressed in U.S. dollars)
Cash and short-term investments $35,885,330 $13,826,992
Other current assets 457,615 1,469,359
Investments 16,487,173 --
Other assets 133,634 352,755
Total assets $52,963,752 $15,649,106
Current liabilities $2,846,116 $2,620,105
Non-current liabilities 93,096 4,863,987
Total liabilities $2,939,212 $7,484,092
Redeemable convertible preferred stock  -- 73,858,722
Stockholders' equity (deficit) 50,024,540 (65,693,708)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) $52,963,752 $15,649,106
Condensed consolidated and combined statements of operations and comprehensive loss
(Unaudited) (Expressed in U.S. dollars)
 JUNE 30,JUNE 30,
Operating expenses        
Research and development $4,551,220 $1,247,103 $6,430,734 $1,820,070
General and administrative 1,081,173 369,757 1,815,997 793,622
Total operating expenses 5,632,393 1,616,860 8,246,731 2,613,692
Other income (expenses)        
Bank charges and financing costs (2,388) (1,769) (456,196) (3,603)
Change in fair value of derivative liabilities 14,501 947,886 928,430 947,886
Amortization and extinguishment of remaining discount on preferred shares upon conversion of preferred shares -- (119,450) (1,884,233) (144,888)
Other income (expenses) 195,521 (21,309) 6,293 (7,472)
  207,634 805,358 (1,405,706) 791,923
Net loss before income taxes (5,424,759) (811,502) (9,652,437) (1,821,769)
Income tax -- -- -- --
Net loss $(5,424,759) $(811,502) $(9,652,437) $(1,821,769)
Other comprehensive income - unrealized gain on available for sale securities 880 -- 880 --
Comprehensive loss $(5,423,879) $(811,502) $(9,651,557) $(1,821,769)